A cross-sectional analysis of 1,387 participants aged 60 years and older from the **NHANES** 2011-2014 investigated the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD), advanced fibrosis likelihood, and cognitive performance.
Key Clinical Findings
MASLD was defined as a hepatic steatosis index of ≥36 combined with at least one cardiometabolic risk factor, excluding excessive alcohol use. Cognitive performance was assessed using a global z-score composite evaluating memory, verbal fluency, and processing speed. Advanced fibrosis likelihood was determined using validated non-invasive scores. The study adjusted for demographic, lifestyle, and cardiometabolic covariates. Findings revealed that MASLD was not associated with global cognition or individual cognitive domains after full adjustment.
Associations with Cognitive Performance
Advanced fibrosis risk was unrelated to cognition except for lower **CERAD** memory scores in conjunction with high **FIB-4** scores. A greater metabolic risk factor burden demonstrated graded associations with poorer cognition; specifically, ≥2 risk factors were linked to lower global cognition and memory, and ≥3 risk factors showed borderline memory impairment. Within the MASLD participant group, ≥2 risk factors were associated with lower global cognition, and ≥3 risk factors were associated with reduced verbal fluency. Processing speed declined only at the highest metabolic burden in models stratified by fibrosis severity.